Trials / Terminated
TerminatedNCT00583557
A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01
A Multi-Center, Open-Label, Continuation Trial of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) Who Completed the Phase 2 Protocol LBRA01
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Human Genome Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a continuation trial of LymphoStat-B™ to evaluate the long-term safety in subjects with Rheumatoid Arthritis that completed study LBRA01 and benefitted from treatment.
Detailed description
This is a multi-center, open label, continuation trial of LymphoStat-B™ in Rheumatoid Arthritis (RA) subjects who achieved at least an ACR20 response in the Phase 2 study LBRA01 (NCT00071812).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | belimumab | IV 10mg/kg Q28 days |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2007-12-31
- Last updated
- 2013-08-07
- Results posted
- 2011-06-29
Locations
48 sites across 2 countries: United States, Poland
Source: ClinicalTrials.gov record NCT00583557. Inclusion in this directory is not an endorsement.